Cautionary StatementSome of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The factors that could cause our actual results to differ materially are identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.keryx.com. The information in our website is not incorporated by reference into this press release and is included as an inactive textual reference only.
Director – Investor Relations
Keryx Biopharmaceuticals, Inc.
E-mail: firstname.lastname@example.orgKeryx Biopharmaceuticals, Inc.Selected Consolidated Financial Data(In Thousands, Except Share and Per Share Amounts)Statements of Operations Information (Unaudited):Three Months Ended March 31,20112010OPERATING EXPENSES:Research and development:Non-cash compensation
242Other research and development
2,554Total research and development
2,796General and administrative:Non-cash compensation
407Other general and administrative
898Total general and administrative
1,305TOTAL OPERATING EXPENSES6,475
(4,101)OTHER INCOME:Interest and other income, net
86NET LOSS$ (6,405)
|SOURCE Keryx Biopharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved